Prof. Dr. Nilüfer BULUT | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 6

1. Clinicopathological Factors Influencing Survival After Trimodality Treatment in Non-Metastatic Esophageal Cancer: A Retrospective Single-Center Study

Yakin M., BULUT N., Kapagan T., Genc S., Oflas U., Yuksel S., et al.

Journal of Clinical Medicine , cilt.15, sa.12, 2026 (SCI-Expanded, Scopus)

2. Prevalence of Malnutrition, Frailty, and Cachexia Across Different Cancer Subtypes: Distribution by Age (<65 and ≥65)

Kapagan T., Kılıc C. E., Arslansoy B., Yontan E., Ozcalimli Z., Ozkan Kardes B. C., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

3. Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK-4/6 Inhibitors Therapy

BULUT N., Kapagan T., Ozmen A., ERDEM G. U.

Immunity, Inflammation and Disease , cilt.14, sa.4, 2026 (SCI-Expanded, Scopus)

4. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Bedir Ş., Kapagan T., Çakan Demirel B., Tokocin M., Yıldırım Ç., Taş S., et al.

Journal of Clinical Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

5. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

Bedir Ş., Yeşilova U. A., Tokoçin M., Çakan Demirel B., Bozkaya Y., Oyman A., et al.

Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

6. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

Fidan M. C., Öztürk A. E., Aydın O., Akdağ G., Türkoğlu E., Çolak R., et al.

Journal of Clinical Medicine , cilt.14, sa.13, 2025 (SCI-Expanded, Scopus)

Creative Commons License

Metrikler

Yayın

6

Yayın (WoS)

6

Yayın (Scopus)

6

H-İndeks (WoS)

1

Atıf (Scopus)

4

H-İndeks (Scopus)

1

Tez Danışmanlığı

2

Açık Erişim

2